Although small molecule inhibitors in the first category, such as P6981 and Surfen, have not been extensively studied preclinically in the cancer context (Xiao et al, 2010; Steven et al, 2020), there has been significant preclinical interest in inhibitors of CREB-CBP interaction across various tumor types (Table 1). This evidence concerns the gene CREB1 and neoplasm.